China Meheco Group 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...1314151617181920212223...212213»
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Ensuring access to novel COVID-19 therapeutics in Pacific island countries and areas. (Pubmed Central) -  Jul 25, 2023   
    Uninterrupted supply and availability of essential medicines in the Pacific region is dependent on external and local sourcing. To overcome procurement barriers and ensure access to novel COVID-19 therapeutics in PICs, WHO's pandemic support to Member States focused on strengthening regulatory requirements, safety monitoring and supply chain activities.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2. (Pubmed Central) -  Jul 18, 2023   
    The binding free energy calculations suggest a possible improvement in the binding affinity of existing inhibitor LCB3 to the mutant forms of the S-protein using simple substitutions at specific positions of the inhibitor. This approach, being general, can be used in different inhibitors and other mutations and help in fighting against SARS-CoV-2.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  EPZ005687 / Eisai, Ipsen, guadecitabine (SGI-110) / Otsuka, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal:  Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study. (Pubmed Central) -  Jul 17, 2023   
    Taken together, the antiviral activities of the highlighted epi-drugs are reported beyond widespread use in combination with anti-cancer agents. The current findings therefore highlight as yet unexplored antiviral potential of epi-drugs suitable for use in patients struggling with chronic immunosuppressive disorders.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
    Journal:  Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. (Pubmed Central) -  Jul 17, 2023   
    Our results indicate that strong pressure from nirmatrelvir or ensitrelvir will select for multiple distinct-resistant lineages that will include both primary resistance mutations that weaken interactions with drug while decreasing enzyme function and compensatory mutations that increase enzyme activity. The comprehensive identification of resistance mutations enables the design of inhibitors with reduced potential of developing resistance and aids in the surveillance of drug resistance in circulating viral populations.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Factors associated with viral rebound among COVID-19 patients receiving oral antivirals. (Pubmed Central) -  Jul 17, 2023   
    The comprehensive identification of resistance mutations enables the design of inhibitors with reduced potential of developing resistance and aids in the surveillance of drug resistance in circulating viral populations. Our data suggest viral rebound after oral antivirals may be more commonly observed among lymphopenic individuals in the context of SARS-CoV-2 Omicron BA.2 variant.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal:  The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. (Pubmed Central) -  Jul 16, 2023   
    Among nonhospitalized COVID-19 patients, who at risk of disease progression, the use of NMV-r is associated with a reduction in the long-term risk of neuropsychiatric sequela, including dementia, depression, insomnia and anxiety disorder. It may be necessary to re-evaluate the use of NMV-r, as a preventive measure to reduce the risk of severe acute disease and post-acute adverse mental health outcomes.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  SARS-CoV-2 and immunosuppressors at cellular level: Some good news. (Pubmed Central) -  Jul 14, 2023   
    We also found that Delta variants were more likely to acquire amino acid substitutions associated with resistance to 3CLpro inhibitors under the selective pressure of this drug compared with Omicron variants. No abstract available
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Review, Journal:  The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review. (Pubmed Central) -  Jul 11, 2023   
    However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China. (Pubmed Central) -  Jul 9, 2023   
    Sensitivity analyses found that the incremental NMB for the vaccinated people aged over 80?years was most sensitive to the efficacy of Paxlovid and the cost-effectiveness probability of Paxlovid increased with its decreasing price. Under the current marketing price of Paxlovid/box (RMB 1,890), using Paxlovid was only cost-effective in people aged over 80 years old regardless of their vaccination status.